Ark Therapeutics Group PLC Cancellation and Publication of Prospectus (0106G)

TIDMAKT

RNS Number : 0106G

Ark Therapeutics Group PLC

26 February 2015

ARK THERAPEUTICS GROUP PLC

Cancellation and Publication of Prospectus

London, UK, 26 February 2015 (LSE: AKT): Ark Therapeutics Group plc ("Ark" or the "Company") announces that, following completion of the acquisition of Premier Veterinary Group Limited on 5 February 2015, constituting a reverse takeover under the Listing Rules, the Company has published a prospectus (the "Prospectus") in connection with the requirement for it to re-apply for listing of its entire issued share capital to the standard listing segment of the Official List of the UK Listing Authority and admission to trading on London Stock Exchange plc's main market for listed securities ("Admission").

It is expected that Admission will become effective and that dealings in the Company's ordinary shares on the London Stock Exchange's main market will re-commence at 08.00 am on 27 February 2015. The Company's TIDM code will be PVG and, on Admission, there will be 13,951,773 ordinary shares of 10 pence each in issue. Therefore, on Admission, the total number of voting rights in the Company is 13,951,773.

The above figure 13,951,773 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Ark under the FCA's Disclosure and Transparency Rules.

Copies of the Prospectus are available from the registered office of the Company at 11 Staple Inn, London WC1V 7QH.

A copy of the Prospectus will also be available for inspection shortly at the Financial Conduct Authority's National Storage Mechanism which can be accessed at www.morningstar.co.uk/uk/NSM and on the Company's website http://www.arktherapeutics.com.

For further information please contact:

   Ark Therapeutics Group plc                                Tel:  [phone] 

Iain G Ross, Non-Executive Chairman

Susan Steven, Non-Executive Director

The contents of this announcement have been prepared by and are the sole responsibility of the Company.

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding Ark's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Ark's control that could cause the actual results, performance or achievements of Ark to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Ark's present and future business strategies and the environment in which Ark will operate in the future. These forward-looking statements speak only as at the date of this announcement. Ark expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in Ark's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

This information is provided by RNS

The company news service from the London Stock Exchange

END

PDIPKADPPBKDFBB